nach oben

Cancer and Metastasis Reviews

Erschienen in:

27.12.2017

miR-155 in cancer drug resistance and as target for miRNA-based therapeutics

verfasst von: Recep Bayraktar, Katrien Van Roosbroeck

Erschienen in: Cancer and Metastasis Reviews | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

Small non-coding microRNAs (miRNAs) are instrumental in physiological processes, such as proliferation, cell cycle, apoptosis, and differentiation, processes which are often disrupted in diseases like cancer. miR-155 is one of the best conserved and multifunctional miRNAs, which is mainly characterized by overexpression in multiple diseases including malignant tumors. Altered expression of miR-155 is found to be associated with various physiological and pathological processes, including hematopoietic lineage differentiation, immune response, inflammation, and tumorigenesis. Furthermore, miR-155 drives therapy resistance mechanisms in various tumor types. Therefore, miR-155-mediated signaling pathways became a potential target for the molecular treatment of cancer. In this review, we summarize the current findings of miR-155 in hematopoietic lineage differentiation, the immune response, inflammation, and cancer therapy resistance. Furthermore, we discuss the potential of miR-155-based therapeutic approaches for the treatment of cancer.

Bartel, D. P. (2009). MicroRNAs: target recognition and regulatory functions. Cell, 136(2), 215–233.PubMedPubMedCentralCrossRef

Ha, M., & Kim, V. N. (2014). Regulation of microRNA biogenesis. Nature Reviews. Molecular Cell Biology, 15(8), 509–524.PubMedCrossRef

Bayraktar, R., et al. (2017). MicroRNA 603 acts as a tumor suppressor and inhibits triple-negative breast cancer tumorigenesis by targeting elongation factor 2 kinase. Oncotarget, 8(7), 11641–11658.PubMedCrossRef

Kanlikilicer, P., et al. (2016). Ubiquitous release of exosomal tumor suppressor miR-6126 from ovarian cancer cells. Cancer Research, 76(24), 7194–7207.PubMedCrossRef

Mangala, L. S., et al. (2016). Improving vascular maturation using noncoding RNAs increases antitumor effect of chemotherapy. JCI Insight, 1(17), e87754.PubMedPubMedCentralCrossRef

Rashed, M. H., et al. (2017). Exosomal miR-940 maintains SRC-mediated oncogenic activity in cancer cells: a possible role for exosomal disposal of tumor suppressor miRNAs. Oncotarget, 8(12), 20145–20164.PubMedPubMedCentralCrossRef

Bentwich, I., et al. (2005). Identification of hundreds of conserved and nonconserved human microRNAs. Nature Genetics, 37(7), 766–770.PubMedCrossRef

Calin, G. A., & Croce, C. M. (2006). MicroRNAs and chromosomal abnormalities in cancer cells. Oncogene, 25(46), 6202–6210.PubMedCrossRef

Calin, G. A., et al. (2002). Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proceedings of the National Academy of Sciences of the United States of America, 99(24), 15524–15529.PubMedPubMedCentralCrossRef

10.

Van Roosbroeck, K., & Calin, G. A. (2016). MicroRNAs in chronic lymphocytic leukemia: miRacle or miRage for prognosis and targeted therapies? Seminars in Oncology, 43(2), 209–214.PubMedPubMedCentralCrossRef

11.

Van Roosbroeck, K., Pollet, J., & Calin, G. A. (2013). miRNAs and long noncoding RNAs as biomarkers in human diseases. Expert Review of Molecular Diagnostics, 13(2), 183–204.PubMedCrossRef

12.

Chen, S., et al. (2015). Host miR155 promotes tumor growth through a myeloid-derived suppressor cell-dependent mechanism. Cancer Research, 75(3), 519–531.PubMedCrossRef

13.

Haasch, D., et al. (2002). T cell activation induces a noncoding RNA transcript sensitive to inhibition by immunosuppressant drugs and encoded by the proto-oncogene, BIC. Cell Immunol, 217(1–2), 78–86.PubMedCrossRef

14.

Babar, I. A., et al. (2012). Nanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of lymphoma. Proceedings of the National Academy of Sciences of the United States of America, 109(26), E1695–E1704.PubMedPubMedCentralCrossRef

15.

Faraoni, I., et al. (2009). miR-155 gene: a typical multifunctional microRNA. Biochimica et Biophysica Acta, 1792(6), 497–505.PubMedCrossRef

16.

Gironella, M., et al. (2007). Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development. Proceedings of the National Academy of Sciences of the United States of America, 104(41), 16170–16175.PubMedPubMedCentralCrossRef

17.

Kong, W., et al. (2014). Upregulation of miRNA-155 promotes tumour angiogenesis by targeting VHL and is associated with poor prognosis and triple-negative breast cancer. Oncogene, 33(6), 679–689.PubMedCrossRef

18.

O’Connell, R. M., et al. (2009). Inositol phosphatase SHIP1 is a primary target of miR-155. Proceedings of the National Academy of Sciences of the United States of America, 106(17), 7113–7118.PubMedPubMedCentralCrossRef

19.

Tili, E., Croce, C. M., & Michaille, J. J. (2009). miR-155: on the crosstalk between inflammation and cancer. International Reviews of Immunology, 28(5), 264–284.PubMedCrossRef

20.

Tili, E., et al. (2011). Mutator activity induced by microRNA-155 (miR-155) links inflammation and cancer. Proceedings of the National Academy of Sciences of the United States of America, 108(12), 4908–4913.PubMedPubMedCentralCrossRef

21.

Van Roosbroeck, K., et al. (2017). Combining anti-Mir-155 with chemotherapy for the treatment of lung cancers. Clinical Cancer Research, 23(11), 2891–2904.PubMedCrossRef

22.

Eis, P. S., et al. (2005). Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proceedings of the National Academy of Sciences of the United States of America, 102(10), 3627–3632.PubMedPubMedCentralCrossRef

23.

Lagos-Quintana, M., et al. (2002). Identification of tissue-specific microRNAs from mouse. Current Biology, 12(9), 735–739.PubMedCrossRef

24.

Tam, W. (2001). Identification and characterization of human BIC, a gene on chromosome 21 that encodes a noncoding RNA. Gene, 274(1–2), 157–167.PubMedCrossRef

25.

Chang, S., et al. (2011). Tumor suppressor BRCA1 epigenetically controls oncogenic microRNA-155. Nature Medicine, 17(10), 1275–1282.PubMedPubMedCentralCrossRef

26.

Vargova, K., et al. (2011). MYB transcriptionally regulates the miR-155 host gene in chronic lymphocytic leukemia. Blood, 117(14), 3816–3825.PubMedCrossRef

27.

Zhao, H., et al. (2017). Transforming growth factor beta1/Smad4 signaling affects osteoclast differentiation via regulation of miR-155 expression. Molecules and Cells, 40(3), 211–221.PubMedPubMedCentral

28.

Gerloff, D., et al. (2015). NF-kappaB/STAT5/miR-155 network targets PU.1 in FLT3-ITD-driven acute myeloid leukemia. Leukemia, 29(3), 535–547.PubMedCrossRef

29.

Georgantas III, R. W., et al. (2007). CD34+ hematopoietic stem-progenitor cell microRNA expression and function: a circuit diagram of differentiation control. Proceedings of the National Academy of Sciences of the United States of America, 104(8), 2750–2755.PubMedPubMedCentralCrossRef

30.

Masaki, S., et al. (2007). Expression patterns of microRNAs 155 and 451 during normal human erythropoiesis. Biochemical and Biophysical Research Communications, 364(3), 509–514.PubMedCrossRef

31.

Hu, Y. L., et al. (2010). HOXA9 regulates miR-155 in hematopoietic cells. Nucleic Acids Research, 38(16), 5472–5478.PubMedPubMedCentralCrossRef

32.

Taganov, K. D., et al. (2006). NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proceedings of the National Academy of Sciences of the United States of America, 103(33), 12481–12486.PubMedPubMedCentralCrossRef

33.

O'Connell, R. M., et al. (2007). MicroRNA-155 is induced during the macrophage inflammatory response. Proceedings of the National Academy of Sciences of the United States of America, 104(5), 1604–1609.PubMedPubMedCentralCrossRef

34.

Kurowska-Stolarska, M., et al. (2011). MicroRNA-155 as a proinflammatory regulator in clinical and experimental arthritis. Proceedings of the National Academy of Sciences of the United States of America, 108(27), 11193–11198.PubMedPubMedCentralCrossRef

35.

Jin, H. M., et al. (2014). MicroRNA-155 as a proinflammatory regulator via SHIP-1 down-regulation in acute gouty arthritis. Arthritis Research & Therapy, 16(2), R88.CrossRef

36.

Keir, M. E., et al. (2008). PD-1 and its ligands in tolerance and immunity. Annual Review of Immunology, 26, 677–704.PubMedCrossRef

37.

Herbst, R. S., et al. (2014). Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature, 515(7528), 563–567.PubMedPubMedCentralCrossRef

38.

Powles, T., et al. (2014). MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature, 515(7528), 558–562.PubMedCrossRef

39.

Yee, D., et al. (2017). MicroRNA-155 induction via TNF-alpha and IFN-gamma suppresses expression of programmed death ligand-1 (PD-L1) in human primary cells. The Journal of Biological Chemistry, 292(50), 20683–20693.

40.

Rodriguez, A., et al. (2007). Requirement of bic/microRNA-155 for normal immune function. Science, 316(5824), 608–611.PubMedPubMedCentralCrossRef

41.

Vigorito, E., et al. (2007). microRNA-155 regulates the generation of immunoglobulin class-switched plasma cells. Immunity, 27(6), 847–859.PubMedPubMedCentralCrossRef

42.

Lu, L. F., et al. (2009). Foxp3-dependent microRNA155 confers competitive fitness to regulatory T cells by targeting SOCS1 protein. Immunity, 30(1), 80–91.PubMedPubMedCentralCrossRef

43.

Yang, L., et al. (2017). MiRNA-155 promotes proliferation by targeting caudal-type homeobox 1 (CDX1) in glioma cells. Biomedicine & Pharmacotherapy, 95, 1759–1764.CrossRef

44.

Liu, Q., et al. (2015). miR-155 regulates glioma cells invasion and chemosensitivity by p38 Isforms in vitro. Journal of Cellular Biochemistry, 116(7), 1213–1221.PubMedCrossRef

45.

D'Urso, P. I., et al. (2012). miR-155 is up-regulated in primary and secondary glioblastoma and promotes tumour growth by inhibiting GABA receptors. International Journal of Oncology, 41(1), 228–234.PubMed

46.

Xue, X., et al. (2016). MiR-21 and MiR-155 promote non-small cell lung cancer progression by downregulating SOCS1, SOCS6, and PTEN. Oncotarget, 7(51), 84508–84519.PubMedPubMedCentralCrossRef

47.

Liu, F., et al. (2017). MiR-155 inhibits proliferation and invasion by directly targeting PDCD4 in non-small cell lung cancer. Thorac Cancer, 8(6), 613–619.PubMedPubMedCentralCrossRef

48.

Al-Haidari, A. A., Syk, I., & Thorlacius, H. (2017). MiR-155-5p positively regulates CCL17-induced colon cancer cell migration by targeting RhoA. Oncotarget, 8(9), 14887–14896.PubMedPubMedCentralCrossRef

49.

Li, T., et al. (2014). miR-155 regulates the proliferation and cell cycle of colorectal carcinoma cells by targeting E2F2. Biotechnology Letters, 36(9), 1743–1752.PubMedCrossRef

50.

Fu, X., et al. (2017). MicroRNA-155-5p promotes hepatocellular carcinoma progression by suppressing PTEN through the PI3K/Akt pathway. Cancer Science, 108(4), 620–631.PubMedPubMedCentralCrossRef

51.

Xie, Q., et al. (2012). Aberrant expression of microRNA 155 may accelerate cell proliferation by targeting sex-determining region Y box 6 in hepatocellular carcinoma. Cancer, 118(9), 2431–2442.PubMedCrossRef

52.

Liu, F., et al. (2015). MiR-155 targets TP53INP1 to regulate liver cancer stem cell acquisition and self-renewal. FEBS Letters, 589(4), 500–506.PubMedCrossRef

53.

Xiang, X., et al. (2011). miR-155 promotes macroscopic tumor formation yet inhibits tumor dissemination from mammary fat pads to the lung by preventing EMT. Oncogene, 30(31), 3440–3453.PubMedPubMedCentralCrossRef

54.

Jiang, S., et al. (2010). MicroRNA-155 functions as an OncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 gene. Cancer Research, 70(8), 3119–3127.PubMedCrossRef

55.

Shen, R., et al. (2015). MiRNA-155 mediates TAM resistance by modulating SOCS6-STAT3 signalling pathway in breast cancer. American Journal of Translational Research, 7(10), 2115–2126.PubMedPubMedCentral

56.

Dinami, R., et al. (2014). miR-155 drives telomere fragility in human breast cancer by targeting TRF1. Cancer Research, 74(15), 4145–4156.PubMedCrossRef

57.

Tiago, D. M., et al. (2016). Matrix Gla protein repression by miR-155 promotes oncogenic signals in breast cancer MCF-7 cells. FEBS Letters, 590(8), 1234–1241.PubMedCrossRef

58.

Bhattacharya, S., et al. (2016). Increased miR-155-5p and reduced miR-148a-3p contribute to the suppression of osteosarcoma cell death. Oncogene, 35(40), 5282–5294.PubMedCrossRef

59.

Rather, M. I., et al. (2013). Oncogenic microRNA-155 down-regulates tumor suppressor CDC73 and promotes oral squamous cell carcinoma cell proliferation: implications for cancer therapeutics. The Journal of Biological Chemistry, 288(1), 608–618.PubMedCrossRef

60.

Peng, Y., et al. (2015). MicroRNA-155 promotes bladder cancer growth by repressing the tumor suppressor DMTF1. Oncotarget, 6(18), 16043–16058.PubMedPubMedCentralCrossRef

61.

Sandhu, S. K., et al. (2012). miR-155 targets histone deacetylase 4 (HDAC4) and impairs transcriptional activity of B-cell lymphoma 6 (BCL6) in the Emu-miR-155 transgenic mouse model. Proceedings of the National Academy of Sciences of the United States of America, 109(49), 20047–20052.PubMedPubMedCentralCrossRef

62.

Huang, X., et al. (2012). Quantitative proteomics reveals that miR-155 regulates the PI3K-AKT pathway in diffuse large B-cell lymphoma. The American Journal of Pathology, 181(1), 26–33.PubMedPubMedCentralCrossRef

63.

Pedersen, I. M., et al. (2009). Onco-miR-155 targets SHIP1 to promote TNFalpha-dependent growth of B cell lymphomas. EMBO Molecular Medicine, 1(5), 288–295.PubMedPubMedCentralCrossRef

64.

Willimott, S., & Wagner, S. D. (2012). miR-125b and miR-155 contribute to BCL2 repression and proliferation in response to CD40 ligand (CD154) in human leukemic B-cells. The Journal of Biological Chemistry, 287(4), 2608–2617.PubMedCrossRef

65.

Costinean, S., et al. (2009). Src homology 2 domain-containing inositol-5-phosphatase and CCAAT enhancer-binding protein beta are targeted by miR-155 in B cells of Emicro-MiR-155 transgenic mice. Blood, 114(7), 1374–1382.PubMedPubMedCentralCrossRef

66.

Dagan, L. N., et al. (2012). miR-155 regulates HGAL expression and increases lymphoma cell motility. Blood, 119(2), 513–520.PubMedPubMedCentralCrossRef

67.

Merkel, O., et al. (2015). Oncogenic role of miR-155 in anaplastic large cell lymphoma lacking the t(2;5) translocation. The Journal of Pathology, 236(4), 445–456.PubMedPubMedCentralCrossRef

68.

Lawrie, C. H., et al. (2007). MicroRNA expression distinguishes between germinal center B cell-like and activated B cell-like subtypes of diffuse large B cell lymphoma. International Journal of Cancer, 121(5), 1156–1161.PubMedCrossRef

69.

Fulci, V., et al. (2007). Quantitative technologies establish a novel microRNA profile of chronic lymphocytic leukemia. Blood, 109(11), 4944–4951.PubMedCrossRef

70.

Kluiver, J., et al. (2005). BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas. The Journal of Pathology, 207(2), 243–249.PubMedCrossRef

71.

Faraoni, I., et al. (2012). MiR-424 and miR-155 deregulated expression in cytogenetically normal acute myeloid leukaemia: correlation with NPM1 and FLT3 mutation status. Journal of Hematology & Oncology, 5, 26.CrossRef

72.

Costinean, S., et al. (2006). Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E(mu)-miR155 transgenic mice. Proceedings of the National Academy of Sciences of the United States of America, 103(18), 7024–7029.PubMedPubMedCentralCrossRef

73.

Rosenbauer, F., & Tenen, D. G. (2007). Transcription factors in myeloid development: balancing differentiation with transformation. Nature Reviews. Immunology, 7(2), 105–117.PubMedCrossRef

74.

Cui, B., et al. (2014). MicroRNA-155 influences B-cell receptor signaling and associates with aggressive disease in chronic lymphocytic leukemia. Blood, 124(4), 546–554.PubMedPubMedCentralCrossRef

75.

Ferrajoli, A., et al. (2013). Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia. Blood, 122(11), 1891–1899.PubMedPubMedCentralCrossRef

76.

Gatto, G., et al. (2008). Epstein-Barr virus latent membrane protein 1 trans-activates miR-155 transcription through the NF-kappaB pathway. Nucleic Acids Research, 36(20), 6608–6619.PubMedPubMedCentralCrossRef

77.

Lu, F., et al. (2008). Epstein-Barr virus-induced miR-155 attenuates NF-kappaB signaling and stabilizes latent virus persistence. Journal of Virology, 82(21), 10436–10443.PubMedPubMedCentralCrossRef

78.

Kluiver, J., et al. (2007). Regulation of pri-microRNA BIC transcription and processing in Burkitt lymphoma. Oncogene, 26(26), 3769–3776.PubMedCrossRef

79.

Garzon, R., et al. (2008). Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin. Proceedings of the National Academy of Sciences of the United States of America, 105(10), 3945–3950.PubMedPubMedCentralCrossRef

80.

Salemi, D., et al. (2015). miR-155 regulative network in FLT3 mutated acute myeloid leukemia. Leukemia Research, 39(8), 883–896.PubMedCrossRef

81.

Wallace, J. A., et al. (2017). miR-155 promotes FLT3-ITD-induced myeloproliferative disease through inhibition of the interferon response. Blood, 129(23), 3074–3086.PubMedPubMedCentralCrossRef

82.

Palma, C. A., et al. (2014). MicroRNA-155 as an inducer of apoptosis and cell differentiation in acute myeloid leukaemia. Molecular Cancer, 13, 79.PubMedPubMedCentralCrossRef

83.

Narayan, N., et al. (2017). Functionally distinct roles for different miR-155 expression levels through contrasting effects on gene expression, in acute myeloid leukaemia. Leukemia, 31(4), 808–820.PubMedCrossRef

84.

Volinia, S., et al. (2006). A microRNA expression signature of human solid tumors defines cancer gene targets. Proceedings of the National Academy of Sciences of the United States of America, 103(7), 2257–2261.PubMedPubMedCentralCrossRef

85.

Zhu, M., et al. (2011). Integrated miRNA and mRNA expression profiling of mouse mammary tumor models identifies miRNA signatures associated with mammary tumor lineage. Genome Biology, 12(8), R77.PubMedPubMedCentralCrossRef

86.

Neilsen, P. M., et al. (2013). Mutant p53 drives invasion in breast tumors through up-regulation of miR-155. Oncogene, 32(24), 2992–3000.PubMedCrossRef

87.

Johansson, J., et al. (2013). MiR-155-mediated loss of C/EBPbeta shifts the TGF-beta response from growth inhibition to epithelial-mesenchymal transition, invasion and metastasis in breast cancer. Oncogene, 32(50), 5614–5624.PubMedPubMedCentralCrossRef

88.

Yanaihara, N., et al. (2006). Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell, 9(3), 189–198.PubMedCrossRef

89.

Zang, Y. S., et al. (2012). MiR-155 inhibits the sensitivity of lung cancer cells to cisplatin via negative regulation of Apaf-1 expression. Cancer Gene Therapy, 19(11), 773–778.PubMedCrossRef

90.

Pouliot, L. M., et al. (2012). Cisplatin sensitivity mediated by WEE1 and CHK1 is mediated by miR-155 and the miR-15 family. Cancer Research, 72(22), 5945–5955.PubMedPubMedCentralCrossRef

91.

Kong, W., et al. (2010). MicroRNA-155 regulates cell survival, growth, and chemosensitivity by targeting FOXO3a in breast cancer. The Journal of Biological Chemistry, 285(23), 17869–17879.PubMedPubMedCentralCrossRef

92.

Lei, C., et al. (2012). Up-regulated miR155 reverses the epithelial-mesenchymal transition induced by EGF and increases chemo-sensitivity to cisplatin in human Caski cervical cancer cells. PLoS One, 7(12), e52310.PubMedPubMedCentralCrossRef

93.

Lv, L., et al. (2016). Effect of miR-155 knockdown on the reversal of doxorubicin resistance in human lung cancer A549/dox cells. Oncology Letters, 11(2), 1161–1166.PubMedCrossRef

94.

Li, B., et al. (2017). Morin promotes prostate cancer cells chemosensitivity to paclitaxel through miR-155/GATA3 axis. Oncotarget, 8(29), 47849–47860.PubMedPubMedCentral

95.

Gu, S., et al. (2017). miR-155 mediates arsenic trioxide resistance by activating Nrf2 and suppressing apoptosis in lung cancer cells. Sci Rep, 7(1), 12155.PubMedPubMedCentralCrossRef

96.

Babar, I. A., et al. (2011). Inhibition of hypoxia-induced miR-155 radiosensitizes hypoxic lung cancer cells. Cancer Biology & Therapy, 12(10), 908–914.CrossRef

97.

Khoshinani, H. M., et al. (2017). Involvement of miR-155/FOXO3a and miR-222/PTEN in acquired radioresistance of colorectal cancer cell line. Japanese Journal of Radiology, 35(11), 664–672.PubMedCrossRef

98.

Lv, X., et al. (2016). Inhibition of microRNA-155 sensitizes lung cancer cells to irradiation via suppression of HK2-modulated glucose metabolism. Molecular Medicine Reports, 14(2), 1332–1338.PubMedCrossRef

99.

Yang, F., Liu, Q., & Hu, C. M. (2015). Epstein-Barr virus-encoded LMP1 increases miR-155 expression, which promotes radioresistance of nasopharyngeal carcinoma via suppressing UBQLN1. European Review for Medical and Pharmacological Sciences, 19(23), 4507–4515.PubMed

100.

Gasparini, P., et al. (2014). Protective role of miR-155 in breast cancer through RAD51 targeting impairs homologous recombination after irradiation. Proceedings of the National Academy of Sciences of the United States of America, 111(12), 4536–4541.PubMedPubMedCentralCrossRef

101.

Narita, M., et al. (2017). Chronic treatment of non-small-cell lung cancer cells with gefitinib leads to an epigenetic loss of epithelial properties associated with reductions in microRNA-155 and -200c. PLoS One, 12(2), e0172115.PubMedPubMedCentralCrossRef

102.

Chiu, C. F., et al. (2016). NF-kappaB-driven suppression of FOXO3a contributes to EGFR mutation-independent gefitinib resistance. Proceedings of the National Academy of Sciences of the United States of America, 113(18), E2526–E2535.PubMedPubMedCentralCrossRef

103.

Kim, J. H., Kim, W. S., & Park, C. (2012). Epstein-Barr virus latent membrane protein-1 protects B-cell lymphoma from rituximab-induced apoptosis through miR-155-mediated Akt activation and up-regulation of Mcl-1. Leukemia & Lymphoma, 53(8), 1586–1591.CrossRef

104.

Pu, J., et al. (2012). Adrenaline promotes cell proliferation and increases chemoresistance in colon cancer HT29 cells through induction of miR-155. Biochemical and Biophysical Research Communications, 428(2), 210–215.PubMedCrossRef

105.

Bayraktar, R., Van Roosbroeck, K., & Calin, G. A. (2017). Cell-to-cell communication: microRNAs as hormones. Molecular Oncology, 11(12), 1673–1686.PubMedPubMedCentralCrossRef

106.

Chen, L., et al. (2014). miR-155 mediates drug resistance in osteosarcoma cells via inducing autophagy. Experimental and Therapeutic Medicine, 8(2), 527–532.PubMedPubMedCentralCrossRef

107.

Patel, G. K., et al. (2017). Exosomes confer chemoresistance to pancreatic cancer cells by promoting ROS detoxification and miR-155-mediated suppression of key gemcitabine-metabolising enzyme, DCK. Br J Cancer, 116(5), 609–619.PubMedCrossRef

108.

Mikamori, M., et al. (2017). MicroRNA-155 controls exosome synthesis and promotes gemcitabine resistance in pancreatic ductal adenocarcinoma. Scientific Reports, 7, 42339.PubMedPubMedCentralCrossRef

109.

Lei, H., & Quelle, F. W. (2009). FOXO transcription factors enforce cell cycle checkpoints and promote survival of hematopoietic cells after DNA damage. Molecular Cancer Research, 7(8), 1294–1303.PubMedCrossRef

110.

Lv, H., et al. (2014). miR-155 inhibitor reduces the proliferation and migration in osteosarcoma MG-63 cells. Experimental and Therapeutic Medicine, 8(5), 1575–1580.PubMedPubMedCentralCrossRef

111.

Feng, M., et al. (2015). Seed targeting with tiny anti-miR-155 inhibits malignant progression of multiple myeloma cells. Journal of Drug Targeting, 23(1), 59–66.PubMedCrossRef

112.

Meng, W., et al. (2012). Anti-miR-155 oligonucleotide enhances chemosensitivity of U251 cell to taxol by inducing apoptosis. Cell Biology International, 36(7), 653–659.PubMedCrossRef

113.

Choi, C. H., et al. (2012). Angiotensin II type I receptor and miR-155 in endometrial cancers: synergistic antiproliferative effects of anti-miR-155 and losartan on endometrial cancer cells. Gynecologic Oncology, 126(1), 124–131.PubMedCrossRef

114.

Zhang, M., et al. (2013). Lactosylated gramicidin-based lipid nanoparticles (Lac-GLN) for targeted delivery of anti-miR-155 to hepatocellular carcinoma. Journal of Controlled Release, 168(3), 251–261.PubMedPubMedCentralCrossRef

115.

Mignacca, L., et al. (2016). Sponges against miR-19 and miR-155 reactivate the p53-Socs1 axis in hematopoietic cancers. Cytokine, 82, 80–86.PubMedCrossRef

116.

Khalife, J., et al. (2015). Pharmacological targeting of miR-155 via the NEDD8-activating enzyme inhibitor MLN4924 (Pevonedistat) in FLT3-ITD acute myeloid leukemia. Leukemia, 29(10), 1981–1992.PubMedPubMedCentralCrossRef

117.

Querfeld, C., et al. (2016). Preliminary results of a phase II trial evaluating MRG-106, a synthetic microRNA antagonist (LNA antimiR) of microRNA-155, in patients with CTCL. Blood, 128(22), 1229.

118.

Catela Ivkovic, T., et al. (2017). microRNAs as cancer therapeutics: a step closer to clinical application. Cancer Letters, 407, 113–122.PubMedCrossRef

119.

Zuo, J., et al. (2017). Inhibition of miR-155, a therapeutic target for breast cancer, prevented in cancer stem cell formation. Cancer Biomarkers. https://doi.org/10.3233/CBM-170642

Titel: miR-155 in cancer drug resistance and as target for miRNA-based therapeutics
verfasst von: Recep Bayraktar
Katrien Van Roosbroeck
Publikationsdatum: 27.12.2017
Verlag: Springer US
Erschienen in: Cancer and Metastasis Reviews / Ausgabe 1/2018
Print ISSN: 0167-7659
Elektronische ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-017-9724-7

Springer Medizin

miR-155 in cancer drug resistance and as target for miRNA-based therapeutics

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2018

MiR-181 family-specific behavior in different cancers: a meta-analysis view

MicroRNAs and metastasis: small RNAs play big roles

RNA interference-based therapy and its delivery systems

Cancer driver G-protein coupled receptor (GPCR) induced β-catenin nuclear localization: the transcriptional junction

Preface

Diagnostic and therapeutic applications of miRNA-based strategies to cancer immunotherapy

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie